Skip to main content
Clinical Trials/NCT02436083
NCT02436083CompletedPhase 4

The Value of Perioperative Antibiotics on the Success of Oral Free Flap Reconstructions

Technical University of Munich0 sites350 target enrollmentStarted: July 2007Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
350
Primary Endpoint
Frequencies of wound infection detected by clinical examinations (daily for 2 weeks, 2 times per week afterwards)

Study Overview

Brief Summary

The purpose of this study is to monitor and compare peri-operative problems and outcomes of reconstructive surgery with microvascular free flaps in the head and neck region between groups of patients treated with perioperative antibiotics and a group of patients without antibiotics.

Detailed Description

Study Design and Patient Recruitment All clinical investigations have been conducted according to the principles expressed in the Declaration of Helsinki. Patient consent was written. Any patient who required reconstructive surgery for oncological reasons within the oral cavity with microvascular free flaps was eligible. Patients receiving preoperative neoadjuvant or previous adjuvant radiation therapy in their medical history were not included in this study as the protocols available are not comparable in doses and effect on the irradiated tissue.14 A prospective study was initiated from July of 2007 to June 2012. All patients were prospectively evaluated.

Postoperative Care The investigators standard regimen was to keep the patient sedated for one night on the intensive care unit and then transfer to the surgical ward. The specific intravenous antibiotic therapy was started 30 minutes before the operation and administered for 10 days.

Data Analysis Recorded parameters included: age, sex, preoperative medical history, American society of Anesthesiologists classification of preoperative status 15, diagnosis, stage of disease, defect localisation, type of microvascular free flap, choice of recipient vessels, flap success, rate and number of operative revisions, primary or secondary reconstruction, type of previous treatment (radiation or surgery), type of previous neck dissection (if any), microvascular complications, the total operative time, wound healing disturbances subdivided into dehiscence and infection at the neck, region of reconstruction, or donor site, and prophylactic antibiotic agent, if used. Infection was defined as a purulent discharge at the wounds.

Descriptive statistics for quantitative variables are given as the mean ± standard deviation. The data were analyzed with the "Statistical Package for the Social Sciences" software (IBM® SPSS® Statistics for Windows, Version 22.0; IBM Corp., Armonk, NY, USA). Figures are generated with SPSS and Microsoft® Office Excel (Microsoft Excel for Windows, release 11.0, 2003, Microsoft Corporation, Redmond, WA, USA). Multiple linear regression analyses were used to determine factors independently associated with the dependent variable wound infection or wound healing disturbances. 95% confidence intervals (95% CI) are also given. Differences were considered to be statistically significant for a two-sided p-value of less than 0.05.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Any patient who required reconstructive surgery for oncological reasons within the oral cavity with microvascular free flaps.

Exclusion Criteria

  • Healthy humans.
  • Patients receiving preoperative neoadjuvant or previous adjuvant radiation therapy in their medical history.

Arms & Interventions

experimental group

Active Comparator

drug administration (antibiotic)

Intervention: antibiotic (use of penicilline, unacid, cefuroxime) (Drug)

Outcomes

Primary Outcomes

Frequencies of wound infection detected by clinical examinations (daily for 2 weeks, 2 times per week afterwards)

Time Frame: participants will be followed for the duration of hospital stay (2 weeks) and a total of 12 weeks

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Technical University of Munich
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

thomas.muecke

responsible consultant

Technical University of Munich

Similar Trials